Xencor (NASDAQ: XNCR) is one of 291 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Xencor to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.
Insider & Institutional Ownership
76.7% of Xencor shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.1% of Xencor shares are held by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Xencor and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for Xencor and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Xencor currently has a consensus price target of $30.25, suggesting a potential upside of 48.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.57%. Given Xencor’s higher possible upside, equities analysts clearly believe Xencor is more favorable than its rivals.
Earnings and Valuation
This table compares Xencor and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Xencor||$87.52 million||$23.62 million||-20.22|
|Xencor Competitors||$290.00 million||$35.57 million||150.30|
Xencor’s rivals have higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Xencor has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Xencor’s rivals have a beta of 0.99, suggesting that their average share price is 1% less volatile than the S&P 500.
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.